Servier underskriver endelig aftale om at erhverve Symphogen, en førende antistof discovery virksomhed, for at styrke Serviers kapacitet inden for antistoffer samt dets forskning og udvikling
03 avr. 2020 10h00 HE
|
Symphogen A/S
Servier styrker dets forskning og udvikling ved at overtage Symphogen’s antistof-pipeline og næste-generations antistof-teknologier.Symphogen bliver Serviers center of excellence inden for...
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
03 avr. 2020 10h00 HE
|
Symphogen A/S
Servier strengthens its R&D pipeline by acquiring Symphogen’s antibody pipeline and next-generation antibody technologies.Symphogen becomes the antibody center of excellence within...
Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials
16 mai 2019 00h59 HE
|
Symphogen A/S
Sym021 a novel anti-PD1 compound currently in Phase 1 clinical trials Copenhagen, 16 May 2019 – Symphogen, a private clinical stage oncology focused biopharmaceutical company with a productive...
Symphogen announces new capital raise and explores strategic options
15 mai 2019 02h00 HE
|
Symphogen A/S
Copenhagen, 15 May 2019 – Today, Symphogen called for an ordinary shareholders meeting to be held on 29 May 2019. At the meeting, Symphogen’s Board of Directors will propose to raise new capital...
Symphogen sammensætter ny bestyrelse til at understøtte selskabets langsigtede udvikling
03 sept. 2018 02h45 HE
|
Symphogen A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Pressemeddelelse København, 3. september...
Symphogen elects new Board members to support the Company's long-term development
03 sept. 2018 02h45 HE
|
Symphogen A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Press Release Copenhagen, 3 September...
Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
30 mai 2018 09h30 HE
|
Symphogen A/S
Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials Seventh Program to enter Clinical Development at Symphogen Symphogen’s antibody platform is...
Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease
30 nov. 2017 04h00 HE
|
Symphogen A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Symphogen Receives Milestone Payment...
Symphogen A/S: Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress
11 sept. 2017 03h45 HE
|
Symphogen A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Symphogen presents detailed results...
Symphogen A/S: Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress
31 août 2017 02h31 HE
|
Symphogen A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Symphogen presents promising...